Melanoma brain metastases (MBM) are a leading cause of morbidity and mortality for patients with advanced disease. Modern systemic therapies do not adequately control brain...
Description: Although immune checkpoint inhibitors (ICI) such as programmed death-1 (PD-1) blockade have made meaningful advances in the treatment of melanoma, drug resista...
While significant progress has been made in developing new therapeutics to control melanoma, the promising clinical outcomes of immune checkpoint inhibitors have drasticall...
Adoptive cell therapy (ACT) using naturally occurring tumor-infiltrating lymphocytes (TIL) can mediate durable tumor regressions and, in some cases, cure in patients with m...
About 40% of melanoma patients have decreased p16, a tumor suppressor protein that inhibits cell proliferation. However, our laboratory and others have found that p16 can r...
Despite recent therapeutic advances, melanoma remains a major burden that is expected to rise faster than any other cancer in the coming decades. Surgery is frequently cura...
Our immune system operates on a balance of cells that that can destroy infected or cancerous tissue with those that prevent attacking healthy tissue. This equilibrium is af...
While immunotherapy has revolutionized the management of advanced melanoma, many patients still do not benefit from this treatment strategy. Indeed, currently available imm...
Cancer treatment was revolutionized when scientists discovered how to activate a patients’ own immune system to fight tumors. Unfortunately, some patients have tumors tha...
Melanoma is the most lethal skin cancer and when detected at an advanced stage in which cells have spread throughout the body (known as metastasis), success of currently av...
Dr. Dennis is a cancer epidemiologist whose research focus has been in melanoma for 30 years including trend analyses of SEER data, risk factor analyses, meta-analyses, and...
Medical Student Award – Emily Higgs
Dec 02, 2025 ET
